These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 2597313

  • 21. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
    Poewe WH, Lees AJ, Stern GM.
    Eur Neurol; 1987; 27 Suppl 1():93-7. PubMed ID: 3322842
    [Abstract] [Full Text] [Related]

  • 22. Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy.
    Rondot P, Ziegler M, Aymard N, Holzer J.
    Eur Neurol; 1987; 27 Suppl 1():114-9. PubMed ID: 3322835
    [Abstract] [Full Text] [Related]

  • 23. [Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
    Liu DK.
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1980 Apr; 13(4):223-6. PubMed ID: 6790255
    [No Abstract] [Full Text] [Related]

  • 24. Therapeutic value of Madopar HBS: judgment after 2 years experience.
    Siegfried J.
    Eur Neurol; 1987 Apr; 27 Suppl 1():98-104. PubMed ID: 3428311
    [Abstract] [Full Text] [Related]

  • 25. [The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment].
    Liu DK.
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1989 Apr; 22(2):95-8, 126-7. PubMed ID: 2791764
    [Abstract] [Full Text] [Related]

  • 26. Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.
    Pakkenberg H, Birket-Smith E, Dupont E, Hansen E, Mikkelsen B, Presthus J, Rautakorpi I, Riman E, Rinne UK.
    Acta Neurol Scand; 1976 May; 53(5):376-85. PubMed ID: 1266576
    [Abstract] [Full Text] [Related]

  • 27. Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
    Quinn NP, Marion MH, Marsden CD.
    Eur Neurol; 1987 May; 27 Suppl 1():105-13. PubMed ID: 3322834
    [Abstract] [Full Text] [Related]

  • 28. Preliminary experience with Madopar HBS: clinical observations and plasma levodopa concentrations.
    Fischer PA, Baas H.
    Eur Neurol; 1987 May; 27 Suppl 1():81-7. PubMed ID: 3322840
    [Abstract] [Full Text] [Related]

  • 29. Levodopa/benserazide ('Madopar') combination therapy in elderly patients with parkinsonism.
    Williams BO, Carlyle D.
    Curr Med Res Opin; 1979 May; 6(1):1-7. PubMed ID: 378553
    [Abstract] [Full Text] [Related]

  • 30. Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations.
    Siirtola T, Sonninen V, Rinne UK.
    Clin Neurol Neurosurg; 1975 May; 78(2):77-88. PubMed ID: 1222507
    [Abstract] [Full Text] [Related]

  • 31. Effect of L-dopa on polycythemia.
    Herishanu Y, Rosenberg P.
    J Am Geriatr Soc; 1977 May; 25(5):218-9. PubMed ID: 853205
    [Abstract] [Full Text] [Related]

  • 32. [Study of the M-H response, of the silent period and of post-tetanic potentiation in subjects with Parkinson's disease during treatment with L-dopa or Madopar].
    Ferro Milone F, Lorizio A, Nordera G.
    Riv Neurol; 1975 May; 45(2):236-46. PubMed ID: 1179114
    [No Abstract] [Full Text] [Related]

  • 33. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.
    Lees AJ.
    Eur Neurol; 1987 May; 27 Suppl 1():126-34. PubMed ID: 3428306
    [Abstract] [Full Text] [Related]

  • 34. Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: two years of follow-up.
    Pacchetti C, Martignoni E, Sibilla L, Bruggi P, Turla M, Nappi G.
    Eur Neurol; 1990 May; 30(6):319-23. PubMed ID: 2289507
    [Abstract] [Full Text] [Related]

  • 35. Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
    Campanella G, Algeri S, Cerletti C, Dolfini E, Jori A, Rinaldi F.
    Eur J Clin Pharmacol; 1977 Apr 20; 11(4):255-61. PubMed ID: 862646
    [No Abstract] [Full Text] [Related]

  • 36. Madopar versus sinemet. A clinical study on their effectiveness.
    Korten JJ, Keyser A, Joosten EM, Gabreëls FJ.
    Eur Neurol; 1975 Apr 20; 13(2):65-71. PubMed ID: 1095374
    [Abstract] [Full Text] [Related]

  • 37. [Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
    Kamenetskiĭ VK.
    Klin Med (Mosk); 1984 Apr 20; 62(4):112-6. PubMed ID: 6737958
    [No Abstract] [Full Text] [Related]

  • 38. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK, Mölsä P.
    Neurology; 1979 Dec 20; 29(12):1584-9. PubMed ID: 574221
    [Abstract] [Full Text] [Related]

  • 39. Ratio of the R and S enantiomers of salsolinol in food and human urine.
    Strolin Benedetti M, Bellotti V, Pianezzola E, Moro E, Carminati P, Dostert P.
    J Neural Transm; 1989 Dec 20; 77(1):47-53. PubMed ID: 2746200
    [Abstract] [Full Text] [Related]

  • 40. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M, Barba C, Ruggieri S, Zamponi A, Agnoli A.
    Riv Neurol; 1974 Dec 20; 44(5):303-30. PubMed ID: 4217465
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.